Asunercept
- Generic Name
- Asunercept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1450882-18-4
- Unique Ingredient Identifier
- F333OQQ9UV
- Background
Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
- Associated Conditions
- -
- Associated Therapies
- -
New therapeutic approach for severe COVID-19: faster recovery and reduction in mortality
A phase 2 clinical trial of a FasL inhibitor, asunercept, showed faster recovery and reduced mortality in severe COVID-19 patients, with an average recovery time of 8 days vs. 13 days in the control group, and a 20% reduction in mortality. The study, published in eClinicalMedicine, suggests the approach could be effective for other respiratory RNA viruses.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath